Cxbladder tests identify high-impact and low-impact tumors


“The purpose of [Cxbladder] Resolve is to identify not only those patients who are at higher risk for urothelial or urinary tract cancer, but those that have a high probability of an aggressive cancer, such as high-grade TA, carcinoma in situ, or T1 to T3,” says Jay Raman, MD, FACS.

In this video, Jay Raman, MD, FACS, discusses how the urinary biomarker Cxbladder tests are used to classify the risk of urothelial cancer in patients with hematuria. Raman is a professor and chair of urology at Penn State Health Milton S. Hershey Medical Center, Penn State University, Pennsylvania.

Related Videos
Dr. Kyle A. Richards in an interview with Urology Times
3d rendered illustration - bladder cancer | Image Credit: © SciePro -
stethoscope on laptop keyboard
Randie White, MD, answers a question during a Zoom video interview
Udit Singhal, MD, answers a question during a Zoom video interview
Hospital hallway | Image Credit: © Paolese -
Related Content
© 2023 MJH Life Sciences

All rights reserved.